Hepatology (Baltimore, Md.)

publication venue for

Aging disrupts hepatocyte zonation homeostasis in mice and humans. 2025
Social determinants of health influence the risk of cirrhosis: A diverse nationwide cohort study. 2025
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data. 2025
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).. 81. 2024
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis. 2024
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis. 2024
MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.. 81. 2024
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019.. 80. 2024
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. 2024
Portable hypothermic oxygenated machine perfusion for organ preservation in liver transplantation: A randomized, open-label, clinical trial.. 79. 2023
Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. 2023
A global action agenda for turning the tide on fatty liver disease.. 79. 2023
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).. 79. 2023
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study.. 78. 2023
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.. 78. 2023
Membrane phospholipid remodeling modulates nonalcoholic steatohepatitis progression by regulating mitochondrial homeostasis.. 79. 2023
HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.. 77. 2023
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis.. 77. 2023
Examining the interim proposal for name change to steatotic liver disease in the US population.. 77. 2023
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.. 77. 2023
The key role of hepatology providers in optimizing reproductive care in patients with liver disease: A call to action.. 78. 2023
Genetic predisposition to porto-sinusoidal vascular disorder: a functional genomic-based, multi-generational family study. 2022
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.. 77. 2022
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.. 77. 2022
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.. 76. 2022
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.. 76. 2022
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.. 76. 2022
S-adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells.. 75. 2021
Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.. 75. 2021
Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.. 74. 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.. 74. 2021
Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.. 74. 2021
State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States.. 74. 2021
Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health. 2021
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. 2021
Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. 2021
Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.. 73. 2021
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. 2021
From NAFLD to MAFLD: Implications of a Premature Change in Terminology.. 73. 2021
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.. 73. 2021
Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience.. 72. 2020
Intestinal Virome in Patients With Alcoholic Hepatitis.. 72. 2020
Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.. 72. 2020
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.. 72. 2020
Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.. 72. 2020
Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort.. 71. 2020
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.. 71. 2019
Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System.. 71. 2019
Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.. 70. 2019
Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial.. 69. 2019
Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury. 70:995-1010. 2019
Preemptive Activation of the Integrated Stress Response Protects Mice From Diet-Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction.. 68. 2018
Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.. 68. 2018
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.. 68. 2018
Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation.. 68. 2018
Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.. 68. 2018
The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.. 67. 2018
A research agenda for curing chronic hepatitis B virus infection.. 67. 2018
Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.. 67. 2017
An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.. 67. 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.. 66. 2017
FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.. 66. 2017
Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.. 65. 2017
Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.. 64. 2016
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.. 64. 2016
Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice.. 63. 2015
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.. 62. 2015
Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B.. 62. 2015
Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes.. 62. 2015
Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.. 62. 2015
Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival.. 61. 2015
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).. 61. 2015
Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt.. 61. 2015
Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus.. 61. 2015
Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment.. 60. 2014
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.. 60. 2014
Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications.. 60. 2014
Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.. 60. 2014
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.. 60. 2014
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis.. 60. 2014
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study.. 59. 2014
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.. 59. 2014
Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.. 59. 2014
Steroid use in acute liver failure.. 59. 2013
Exposure to ionizing radiation during liver transplantation evaluation, waitlist time, and in the postoperative period: a cause for concern.. 59. 2013
Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials.. 58. 2013
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients.. 58. 2013
Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.. 58. 2013
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.. 57. 2013
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. 56. 2012
Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women.. 56. 2012
Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma.. 55. 2012
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.. 55. 2011
Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells.. 54. 2011
Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.. 54. 2011
Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.. 55. 2011
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.. 54. 2011
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.. 54. 2011
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.. 54. 2011
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.. 52. 2010
Hepatitis B virus-DNA level and basal core promoter A1762T/G1764A mutation in liver tissue independently predict postoperative survival in hepatocellular carcinoma.. 52. 2010
Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice.. 51. 2010
Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury.. 51. 2010
Effect of hepatitis C virus and its treatment on survival.. 50. 2009
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells.. 48. 2008
Clinical risk factors for portopulmonary hypertension.. 48. 2008
Dendritic cells are required for effective cross-presentation in the murine liver.. 47. 2008
Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate.. 47. 2008
Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.. 46. 2007
The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity.. 46. 2007
Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.. 46. 2007
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.. 46. 2007
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.. 45. 2007
Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion.. 45. 2007
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.. 45. 2007
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells.. 43. 2006
Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors.. 42. 2005
A biphasic response of hepatobiliary cholesterol metabolism to dietary fat at the onset of obesity in the mouse.. 41. 2005
Wilson disease in septuagenarian siblings: Raising the bar for diagnosis.. 41. 2005
Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.. 40. 2004
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees.. 39. 2004
Prevalence of HBV precore/core promoter variants in the United States.. 38. 2003
Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi.. 33. 2001
Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.. 33. 2001
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding.. 31. 2000
Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.. 31. 2000
Decision-analysis of transjugular intrahepatic portosystemic shunt versus distal splenorenal shunt for portal hypertension.. 29. 1999
Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins.. 28. 1998
Pharmacological expression in rat hepatocytes of a gene transferred by an adenovirus vector enabled by a chimeric promoter containing multiple cyclic adenosine monophosphate response elements.. 27. 1998
Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat.. 26. 1997
Transmembrane translocation of phosphatidylcholines and biliary lipid secretion: evidence for "flippases" in the canalicular plasma membrane.. 24. 1996
Liver function in early Lyme disease.. 23. 1996
Endoscopic therapy for cholangitis in cirrhosis.. 23. 1996
Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases.. 22. 1995
Rapid and efficient gene transfer in Human hepatocytes by herpes viral vectors.. 22. 1995
Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: differing effects of cyclosporine and FK 506.. 19. 1994
Coexpression of erythropoietin and heme oxygenase genes in Hep3B cells.. 17. 1993
Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma.. 16. 1992
The effect of liver denervation on hepatic hemodynamics during hypovolemic shock in swine.. 15. 1992
Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects.. 13. 1991
Detection of antibodies against hepatitis B virus polymerase antigen in hepatitis B virus-infected patients.. 10. 1989
Pharmacokinetics of tin-mesoporphyrin in man and the effects of tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria.. 9. 1989
Sn-protoporphyrin lowers serum bilirubin levels, decreases biliary bilirubin output, enhances biliary heme excretion and potently inhibits hepatic heme oxygenase activity in normal human subjects.. 8. 1988
Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis.. 8. 1988
The fluidity of liver plasma membranes from patients with different types of liver injury.. 6. 1986
Functional properties of isolated hepatocytes from ethanol-treated rat liver.. 5. 1985
Transmission of ground squirrel hepatitis virus to homologous and heterologous hosts.. 5. 1985
Time course and mechanism of alterations in proton relaxation during liver regeneration in the rat.. 5. 1985
Control of heme oxygenase and plasma levels of bilirubin by a synthetic heme analogue, tin-protoporphyrin.. 4. 1984
Reply.. 68. 2018
Reply.. 64. 2016
Reply: To PMID 24954365.. 62. 2015
Reply: To PMID 24954365.. 61. 2015
Reply: To PMID 23929808.. 60. 2014
Diagnostic utility of chromosome 17 and p16 abnormalities in fluorescence in situ hybridization tests in primary sclerosing cholangitis.. 52. 2010
WIN-R revisited: Response to editorial.. 47. 2008
Evasive maneuvers by hepatitis C virus.. 38. 2003
Quality of life with pegylated interferon therapy for hepatitis C.. 36. 2002
Bacterial translocation in acute and chronic portal hypertension.. 20. 1994
Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights. 2020
Inflammasome and toll-like receptor 9: Partners in crime in toxic liver injury. 2009
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys. 2023
Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark. 2021
Reply: To PMID 23703931. 2014
Blind beta blockade. 2001
Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. 1999
Report of the Multisociety Task Force on GI training. 2009
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?. 76. 2022
AASLD Educating and Engaging in the Digital Age: Editorial from Communications and Technology Committee. 2021
Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.. 74. 2021
Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD.. 68. 2018
The patient's perspective in hepatitis C.. 39. 2004
Multi-Disciplinary Clinic Models: A Paradigm of Care for Management of Non-Alcoholic Fatty Liver Disease (NAFLD). 2021
A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. 2019
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. 2015
Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. 2012
Sorafenib: where do we go from here? 2010
Is CD81 the key to hepatitis C virus entry? 1999
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. 2022
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art. 2021
Thyroid Hormone Signaling and the Liver. 2020
HCV in Women and Pregnancy. 2019
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 2015

VIVO Weill Cornell Medical College

Hepatology (Baltimore, Md.) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)